Table 7. Clinical analysis of the drug resistant and non-resistant TBM patients.
| Chemotherapy regimen changes (n = 2) | Drug-resistant patients (n = 14), n (%) | Non-resistant patients (n = 21), n (%) |
|---|---|---|
| 2 (100) | 0 | |
| Clinical features | ||
| Extrameningeal TB (n = 17)** | 13 (94.1) | 1 (4.7) |
| Headache (n = 27) | 10 (71.4) | 17 (80.9) |
| Fever (n = 27) | 12 (85.7) | 15 (71.4) |
| Altered mentation (n = 14) | 6 (42.8) | 8 (38.1) |
| Vomiting (n = 11)* | 7 (50.0) | 4 (19.1) |
| MRI/CT abnormalities | ||
| Meningeal (n = 22)* | 11 (78.57) | 11 (52.4) |
| Tuberculoma (n = 15) | 6 (42.9) | 9 (42.9) |
| Prognosis | ||
| Poor prognosis (n = 5)** | 4 (28.6) | 1 (4.7) |
| Chemotherapy for change (n = 2)* | 2 (14.3) | 0 (0) |
| CSF analysis | ||
| High opening pressure (n = 14)** | 11 (78.6) | 3 (14.3) |
| High CSF leukocyte count (n = 31) | 13 (92.9) | 18 (85.7) |
| Low CSF glucose (n = 26) | 9 (64.3) | 17 (80.9) |
| High CSF protein (n = 32) | 13 (92.9) | 19 (90.4) |
| Low CSF chlorinate (n = 28) | 12 (85.7) | 16 (76.1) |
| High IgG index (n = 5) | 2/9 (22.2) | 3/14 (21.4) |
| CSF IgG synthesis rate (n = 23) | 7/9 (77.8) | 11/14 (78.6) |
*p < 0.05.
**p < 0.01.